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  The product of this project is a clinical pathway for the evaluation and management of hyperbilirubinemia in the inpatient pediatrics unit at LVHN (Figure 2). This pathway 
consists of a change in the method of phototherapy delivery to maximize body surface 
area exposure, standardized nursing and physician protocols, and an accompanying 
EMR order set (Figure 3). Within the first two months, it was utilized in the care of twelve 




The goal of instituting a standardized approach to the identification and 
management of hyperbilirubinemia in term and near-term newborns is 
to reduce the incidence of severe hyperbilirubinemia, reduce variability 
in practice, optimize the delivery of phototherapy, improve safety and 
clinical outcomes, and decrease cost pertaining to hospital length-of-
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Tollgate #2: CH PQIC
09.22.17






1) GA >/= 35 wks
2) Previously healthy
3) Age </= 14 days
4) TSB at or above threshold 
for initiation of phototherapy
EXCLUSION CRITERIA:
1) Direct byperbili
2) Rectal temp >/= 100.4 or 
signs of infection





Tollgate #3: CH PQIC
12.06.17
Multidisciplinary meetings with:
• Products Committee for approval of new supplies (e.g. multi-use curtains)
• Mother infant Care Committee (week prior to 10.03/17) to present changes 
to be made to phototherapy policy (to cover inpatient wards, newborn 
nursery, and mother/baby unit)
• Clinical Consensus Committee Work Group (10.18.17) to address findings 
of preliminary chart review
Develop plan for 
monitoring 




1) Dec length of stay
2) Dec percentage readmitted 
within 48 hours
3) Dec percentage 
inappropriately receiving 
phototherapy
4) Inc provider compliance 
with pathway
Developed Nursing Education (didactic 
session, TLC education for RN review, 
hands-on training for phototherapy set-up) 
& Pediatrics Resident Education (01.03.18 
– didactic presentation with Q&A)
Quarterly 
Updates 
presented at CH 
PQIC
Add Pathway to 
Policy Tech










4 Phases to Implementing Clinical Pathways
•  Hyperbilirubinemia is a common cause of hospital admission in 
neonates. 
•  Severe hyperbilirubinemia can lead to acute bilirubin encephalopathy 
and kernicterus, a form of irreversible neurological damage. 
•  The current AAP Clinical Practice Guideline emphasizes 
the importance of a universal, systematic assessment of 
hyperbilirubinemia and the provision of prompt intervention, when 
needed. 
•  Several large children’s hospitals including CHOP and Seattle 
Children’s have established clinical pathways using the AAP 
guideline.
•  Seattle Children’s Hospital found that a standard care pathway for 
neonatal jaundice can reduce cost and length of stay.
•  LVHN has nearly 4,500 deliveries annually and the Children’s Hospital 
has 30 pediatric-specific subspecialties and a level IV NICU. 
•  A hyperbilirubinemia pathway does not currently exist at LVHN. 
•  A retrospective chart review indicated that 52% of infants admitted 
to the inpatient pediatric unit were inappropriately admitted for 
phototherapy and, of those, 52% lacked another outstanding reason 
for admission.
The completion of the project involved closely working with CH PQIC to 
create the clinical pathway. Figure 1 illustrates the steps in this process, 
from conception to approval. The pathway was available for use on 
01/01/18 and was made live on the hospital network on 02/01/18. 
Finally, a post-pathway retrospective chart review was conducted on 
two months of pilot data.
Data and feedback from January and February 2018 suggest that:
•  The pathway seems practical for use and feasible to follow,
•  Triple phototherapy delivered in a way to maximize body surface area exposure appears to be 
effective in lowering bilirubin and does not appear to adversely affect temperature stability,
•  There is an increase in documentation of neurotoxicity risk level in the EMR,
•  There is an increase in appropriate stratification of neurotoxicity risk, and
•  There is an increase in treatment of babies who met criteria for phototherapy and a decrease in 
treatment of babies who did not meet criteria.
Reduction in inappropriate treatment initiation suggests that the pathway may decrease unnecessary 
admissions, which may decrease exposure to HAIs in a vulnerable population, improve overall patient 
outcomes, and decrease healthcare costs.
Next Steps
 
•  Further data collection and analysis
•  Development of a process for data collection and tracking of outcome metrics with Enterprise 
Analytics 
•  Creation of EMR note templates and dot phrases to be shared with the network’s providers
•  Creation of an educational outreach component to be distributed to the network’s providers
•  Completion of newborn nursery unit hyperbilirubinemia pathway (currently in the development stage)
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Pathway Creation Process
Figure 2.
Figure 1. Flowchart 
depicting steps taken 
in the creation of 
hyperbilirubinemia 
pathway. Included 
in this process are 
multidisciplinary meetings, 
Children’s Performance 
and Quality Improvement 
Committee (CH PQIC) 
meetings, and the creation 
of inclusion and exclusion 
criteria and metrics. 
Flowchart was adapted 
from LVHN’s CH PQIC 
“Summary Process of 
Pathway Creation” form.
Figure 3. 
Figure 4. Comparison of babies admitted before and after 01/01/18. 2017 data has N = 68. 2018 data has N = 12. 
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